Postmenopausal hormone replacement therapy — clinical implications

Ravn, Susanne Holst; Rosenberg, Jacob; Bostofte, Erik

doi:10.1016/0028-2243(94)90213-5

Cited by 29 publications

(13 citation statements)

References 169 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A delay in gastric and enteric transit has been established during the perimenopausal period (6)(7)(8)(9)(10). Hormone replacement therapy for postmenopausal women has the advantages of relieving symptoms, such as hot flushes, and preventing the risk of osteoporosis, but increases the incidence of gallstones (7,10,11).…”

mentioning

confidence: 99%

Delay in gallbladder emptying during the perimenopausal period

Petroianu

Oliveira

Vieira

2000

Braz J Med Biol Res

View full text Add to dashboard Cite

A pilot study has ascribed an important role in gallbladder motility and emptying to the perimenopausal period. To assess the effect of this period on gallbladder emptying and cholelithogenesis, 25 women in the perimenopausal period without gallbladder disease were submitted to cholangiography and two ultrasound exams. The time for gallbladder emptying and the presence of cholelithiasis were assessed. All patients presented a delay in gallbladder emptying with no relationship to the pre-or postmenopausal period. This finding was not related to lithogenesis. Gallbladder emptying time is longer during the perimenopausal period.

show abstract

mentioning

confidence: 99%

Delay in gallbladder emptying during the perimenopausal period

Petroianu

Oliveira

Vieira

2000

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…Replacement of oestrogen, and more specifically oestradiol, which is the major oestrogen in premenopausal women, can prevent the symptoms of menopause [5] and is thought to have a beneficial effect on the incidence of osteoporosis [6][7][8] and cardiovascular disease in postmenopausal women.…”

Section: Discussionmentioning

confidence: 99%

“…Blood samples were taken prior to patch application, then 1, 2, 3, 4,6,8,10,12,16,20,24,36,48,72,96,120,144,168,180,192 and 216 h after application. The primary pharmacokinetic parameters C max (mean peak plasma concentration) and AUC 0-168 (area under the plasma concentration curve from the time of application to the time of removal) were calculated with and without correction for baseline.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacokinetics of Fem7<sup>®</sup>, a Once-Weekly, Transdermal Oestrogen Replacement System in Healthy, Postmenopausal Women

Geyer

Gerrits²,

Renoux³

et al. 1999

Gynecol Obstet Invest

View full text Add to dashboard Cite

This open-label, randomized study in 36 healthy postmenopausal women, investigated the pharmacokinetics of Fem7^® (an oestradiol matrix-type patch), at doses of 25, 50, 75 and 100 μg/24 h, applied once weekly. Maximum plasma concentrations of oestradiol and oestrone were observed 14–20 h after patch application, remaining within the therapeutic range until removal, and returning to baseline within 12 h thereafter. Plasma oestradiol concentrations increased in a dose-dependent manner for all four doses, and plasma oestrone increased for the three highest doses. Fem7 treatment was well tolerated at all four doses and no severe adverse reactions were reported. Fem7 is a convenient and well-tolerated form of hormone-replacement therapy that delivers oestradiol in a consistent and predictable manner.

show abstract

“…1,2 If menopause were a cardiovascular risk factor, it could be defined as the most incident one. However, the question whether cardiovascular changes appearing in women in later life are attributable to their hormonal status [2][3][4][5][6][7][8][9][10][11][12] rather than to advancing age [13][14][15][16] is still debatable.…”

Section: Introductionmentioning

confidence: 99%

Blood pressure and metabolic profile after surgical menopause: comparison with fertile and naturally-menopausal women

et al. 2000

View full text Add to dashboard Cite

In 1978 a random sample (367 men and 568 women aged 18-65 years) taken from the general population of a north-eastern Italian town was screened for cardiovascular risk; 16 years later, the women were invited to a second screening. Three groups were identified at the initial screening (fertile, naturally menopausal and surgically menopausal) and four in the longitudinal study (137 remained fertile during the whole study, 205 became naturally menopausal, 56 were ovariectomised and 127 were already going through the menopause). The protocol included a questionnaire, blood pressure (BP) measurement, and blood exams. Continuous variables were adjusted for confounders. Systolic BP, prevalence of hypertension, cholesterol, glycaemia and uricaemia were similar, whereas diastolic and triglycerides (TG) were lower in surgically-menopausal than in fertile women (P Ͻ 0.001). No significant difference in 16 years' variation from baseline was observed between

show abstract

Postmenopausal hormone replacement therapy — clinical implications

Cited by 29 publications

References 169 publications

Delay in gallbladder emptying during the perimenopausal period

Delay in gallbladder emptying during the perimenopausal period

Pharmacokinetics of Fem7<sup>®</sup>, a Once-Weekly, Transdermal Oestrogen Replacement System in Healthy, Postmenopausal Women

Blood pressure and metabolic profile after surgical menopause: comparison with fertile and naturally-menopausal women

Contact Info

Product

Resources

About